BlackRock, Inc. 13D and 13G filings for Halozyme Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-01-23 11:52 am Sale |
2023-12-31 | 13G | Halozyme Therapeutics, Inc. HALO |
BlackRock Inc. BLK |
18,629,818 14.100% |
-566,243 (-2.95%) |
Filing |
| 2023-02-10 2:11 pm Unchanged |
2022-12-31 | 13G | Halozyme Therapeutics, Inc. HALO |
BlackRock Inc. BLK |
19,196,061 14.200% |
0 (Unchanged) |
Filing |
| 2023-01-26 08:52 am Purchase |
2022-12-31 | 13G | Halozyme Therapeutics, Inc. HALO |
BlackRock Inc. BLK |
19,196,061 13.600% |
981,990 (+5.39%) |
Filing |
| 2023-01-20 3:00 pm Sale |
2022-12-31 | 13G | Halozyme Therapeutics, Inc. HALO |
BlackRock Inc. BLK |
18,214,071 13.600% |
-1,225,792 (-6.31%) |
Filing |
| 2022-01-28 1:54 pm Purchase |
2021-12-31 | 13G | Halozyme Therapeutics, Inc. HALO |
BlackRock Inc. BLK |
19,439,863 13.800% |
958,556 (+5.19%) |
Filing |
| 2021-01-26 2:22 pm Sale |
2020-12-31 | 13G | Halozyme Therapeutics, Inc. HALO |
BlackRock Inc. BLK |
18,481,307 13.700% |
-202,823 (-1.09%) |
Filing |
| 2020-12-08 4:56 pm Purchase |
2020-11-30 | 13G | Halozyme Therapeutics, Inc. HALO |
BlackRock Inc. BLK |
18,684,130 13.800% |
6,587,333 (+54.46%) |
Filing |